Public Perceptions of Presymptomatic Testing for Alzheimer Disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective To explore, among online visitors to an Alzheimer’s disease (AD) website, the self-expressed desire for, envisioned reaction to, and basic understanding of presymptomatic AD-related genetic and biomarker tests. Patients and Methods Information about presymptomatic testing, and an online multiple choice format survey were posted from November 1, 2012 through June 20, 2013 on the AD Prevention Registry website (www.endALZnow.org). Results Of 4036 respondents, 80.8% wanted genetic testing if paid by insurance; 58.7% if it would cost them at least $100. 80.2% wanted biomarker testing. If found to be at high risk for AD, 90.5% endorsed that they would “pursue a healthier lifestyle,” but 11.6% endorsed “seriously consider suicide.” The implication of a positive genetic test was incorrectly understood by 13.1%, and 32.6% failed to view a positive biomarker test as evidence of either increased risk for or the presence of AD. Conclusion Despite efforts to increase public awareness of AD, our survey results suggest that greater education of the public is needed. Interested patients should probably undergo psychological screening to identify those at high risk of adverse psychological outcomes, and disclosure of presymptomatic test results should be anchored to tangible constructive action plans such as healthy lifestyle changes, long term care planning, and when available and appropriate, participation in research trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Self-citationPerceptions of Familial Risk in those Seeking a Genetic Risk Assessment for Alzheimer's Disease
Hiraki, S., Chen, C. A., Roberts, J. S., Cupples, L. A., & Green, R. C. (2009) · Journal of Genetic Counseling · doi:10.1007/s10897-008-9194-8 · Cited by 30
Cited by
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
“5% of participants endorsed that they would “pursue a healthier lifestyle” in the case of high risk for AD [274].”
BackgroundCaselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
“biomarker testing.(130) With the advent of presymptomatic trials as well as the commercial availability of genetic tests, such testing is happening, despite these caveats.”
Self-citationFriedman, B. B., Suri, S., Solé-Padullés, C., Düzel, S., Drevon, C. A., Baaré, W. F. C., Bartrés-Faz, D., Fjell, A. M., Johansen-Berg, H., Madsen, K. S., et al. (2020) · The Gerontologist · doi:10.1093/geront/gnz155 · Cited by 20
Metadata
- Authors
- Caselli, R. J., Langbaum, J., Marchant, G. E., Lindor, R. A., Hunt, K. S., Henslin, B. R., Dueck, A. C., & Robert, J. S.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 89
- Issue
- 10
- Pages
- 1389-1396
- ISSN
- 0025-6196 (ISSN-L)
- OpenAlex
- W2002651673
- Cited by
- 72
- References
- 2
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Public Perceptions of Presymptomatic Testing for Alzheimer Disease. https://app.cochat.ai/papers/10.1016/j.mayocp.2014.05.016
- The paper
- Caselli, R. J., Langbaum, J., Marchant, G. E., Lindor, R. A., Hunt, K. S., Henslin, B. R., Dueck, A. C., & Robert, J. S. (2014). Public Perceptions of Presymptomatic Testing for Alzheimer Disease. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2014.05.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.